Molecular Subtyping of Triple-Negative Breast Cancer and the Latest Advances in Treatment for Each Subtype

乳腺癌作为全球女性发病率最高的恶性肿瘤，虽然目前综合性治疗的方法显著降低了患者的死亡率，但仍有一部分患者尤其是三阴性乳腺癌(triple negative breast cancer, TNBC)的患者无法从现有的治疗手段中获益。大量学者通过对TNBC分子分型的深入研究，发现了免疫疗法有望填补化疗的不足，同时对TNBC的治疗现状及预后也可产生深远的影响。本文旨在对TNBC的分子分型及其治疗的最新进展做一综述。Breast cancer is the malignant tumor with the highest incidence among women in the world. Although the current comprehensive treatment methods have significantly reduced the mortality rate of patients, there are still some patients, especially those with triple negative breast cancer (TNBC), who cannot benefit from the existing treatment methods. A large number of scholars have deeply studied the molecular typing of TNBC, and found that immunotherapy is expected to fill the deficiency of chemotherapy, and at the same time, it can also have a far-reaching impact on the treatment status and prognosis of TNBC. The purpose of this paper is to review the latest progress in molecular typing and treatment of TNBC.